Top

Pituitary

Published in:

01-02-2017

Complications of acromegaly: thyroid and colon

Authors: Amit Tirosh, Ilan Shimon

Published in: Pituitary | Issue 1/2017

Abstract

Introduction

In acromegaly the long-term exposure to high growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels may result in specific complications in different human organs, including the thyroid gland and the colon.

Materials and Methods

We will review here the evidence available regarding the characteristic thyroid and colon complications in acromegaly.

Results

This review summarizes the published data observing noncancerous structural abnormalities (thyroid nodules, colonic polyps) and thyroid and colon cancer in patients diagnosed with acromegaly.

Conclusion

Thyroid micro-carcinomas are probably over-diagnosed among acromegalic patients. In regard to colon cancer, there is no sufficient data to suggest that colon cancer risk is higher in acromegaly compared to the general population.

Cohen P, Clemmons DR, Rosenfeld RG et al (2000) Does the GH–IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297–305. doi:10.1054/ghir.2000.0171 CrossRefPubMed

Boguszewski CL, Ayuk J (2016) Management of endocrine disease: acromegaly and cancer: an old debate revisited. Eur J Endocrinol. doi:10.1530/EJE-16-0178 PubMedCentral

Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (London, England) 363:1346–1353. doi:10.1016/S0140-6736(04)16044-3 CrossRef

Jenkins PJ, Besser M (2001) Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 86:2935–2941. doi:10.1210/jcem.86.7.7634 CrossRefPubMed

Melmed S (2001) Acromegaly and cancer: Not a problem? J Clin Endocrinol Metab 86:2929–2934. doi:10.1210/jcem.86.7.7635 CrossRefPubMed

Roelfsema F, Biermasz NR, Frolich M et al (2009) Diminished and irregular thyrotropin secretion with preserved diurnal rhythm in patients with active acromegaly. J Clin Endocrinol Metab 94:1945–1950. doi:10.1210/jc.2009-0174 CrossRefPubMed

Miyakawa M, Saji M, Tsushima T et al (1988) Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor 1 levels. J Clin Endocrinol Metab 67:973–978CrossRefPubMed

Lamberg BA, Pelkonen R, Aro A, Grahne B (1976) Thyroid function in acromegaly before and after transsphenoidal hypophysectomy followed by cryoapplication. Acta Endocrinol (Copenh) 82:254–266

Geelhoed-Duijvestijn PH, Roelfsema F, Schröder-van der Elst JP et al (1992) Effect of administration of growth hormone on plasma and intracellular levels of thyroxine and tri-iodothyronine in thyroidectomized thyroxine-treated rats. J Endocrinol 133:45–49CrossRefPubMed

10.

Damjanović SS, Petakov MS, Raicević S et al (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154. doi:10.1210/jcem.85.1.6296 CrossRefPubMed

11.

Gøtzsche LS, Flyvbjerg A, Marshall S et al (1991) The influence of growth hormone and thyroxine on iodothyronine deiodinase activity in the liver, kidney and brown adipose tissue in hypophysectomized rats. Acta Endocrinol (Copenh) 125:219–226

12.

Roelfsema F, Frölich M (1991) Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. J Clin Endocrinol Metab 72:77–82. doi:10.1210/jcem-72-1-77 CrossRefPubMed

13.

Wuster C, Steger G, Schmelzle A et al (1991) Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly. Horm Metab Res 23:131–134. doi:10.1055/s-2007-1003632 CrossRefPubMed

14.

Gasperi M, Martino E, Manetti L et al (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25:240–245. doi:10.1007/BF03343997 CrossRefPubMed

15.

Marzullo P, Cuocolo A, Ferone D et al (2000) Cardiac effect of thyrotoxicosis in acromegaly. J Clin Endocrinol Metab 85:1426–1432. doi:10.1210/jc.85.4.1426 PubMed

16.

Chanson P, Salenave S, Kamenicky P et al (2009) Acromegaly. Best Pract Res Clin Endocrinol Metab 23:555–574. doi:10.1016/j.beem.2009.05.010 CrossRefPubMed

17.

Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152. doi:10.1210/er.2002-0022 CrossRefPubMed

18.

Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. doi:10.1210/jc.2014-2700 CrossRefPubMed

19.

Gatto F, Barbieri F, Castelletti L et al (2011) In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary 14:141–147. doi:10.1007/s11102-010-0271-2 CrossRefPubMed

20.

Lamberts SW, Zuyderwijk J, den Holder F et al (1989) Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50:44–50CrossRefPubMed

21.

Amlashi FG, Tritos NA (2016) Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine. doi:10.1007/s12020-016-0863-3 PubMed

22.

Atkinson H, England JA, Rafferty A et al (2013) Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 94:226–229. doi:10.1111/iep.12024 CrossRefPubMedPubMedCentral

23.

Razzore P, Colao A, Baldelli R et al (1999) Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol (Oxf) 51:159–164. doi:10.1046/j.1365-2265.1999.00812.x CrossRef

24.

Carvalho P, Lau E, Carvalho D (2015) Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results. Pituitary 18:844–860. doi:10.1007/s11102-015-0661-6 CrossRefPubMed

25.

Sarkar S, Rajaratnam S, Chacko G, Chacko AG (2014) Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg 126:190–195. doi:10.1016/j.clineuro.2014.09.004 CrossRefPubMed

26.

Berkmann S, Fandino J, Müller B et al (2012) Pituitary surgery: experience from a large network in Central Switzerland. Swiss Med Wkly 142:w13680. doi:10.4414/smw.2012.13680 PubMed

27.

Haugen BR, Alexander EK, Bible KC et al (2015) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. doi:10.1089/thy.2015.0020

28.

Tode B, Serio M, Rotella CM et al (1989) Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab 69:639–647CrossRefPubMed

29.

Cheung NW, Boyages SC (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46:545–549. doi:10.1046/j.1365-2265.1997.1680985.x CrossRef

30.

Yoshinari M, Tokuyama T, Kuroda T et al (1992) Preserved thyroidal secretion of thyroxine in acromegalic patients with suppressed hypophyseal secretion of thyrotrophin. Clin Endocrinol (Oxf) 36:355–360CrossRef

31.

Wolinski K, Czarnywojtek A, Ruchala M (2014) Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review. PLoS ONE. doi:10.1371/journal.pone.0088787

32.

Dagdelen S, Cinar N, Erbas T (2014) Increased thyroid cancer risk in acromegaly. Pituitary 17:299–306. doi:10.1007/s11102-013-0501-5 CrossRefPubMed

33.

Balkany C, Cushing GW (1995) An association between acromegaly and thyroid carcinoma. Thyroid 5:47–50. doi:10.1089/thy.1995.5.47 CrossRefPubMed

34.

Dos Santos MCC, Nascimento GC, Nascimento AGC et al (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16:109–114. doi:10.1007/s11102-012-0383-y CrossRefPubMed

35.

Herrmann BL, Baumann H, Janssen OE et al (2004) Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 112:225–230. doi:10.1055/s-2004-817967 CrossRefPubMed

36.

de Uchoa HBDMP, Lima GAB, Corrêa LL et al (2013) Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol 57:685–690CrossRefPubMed

37.

Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13:242–248. doi:10.1007/s11102-010-0224-9 CrossRefPubMed

38.

Popovic V, Damjanovic S, Micic D et al (1998) Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol (Oxf) 49:441–445. doi:10.1046/j.1365-2265.1998.00536.x CrossRef

39.

Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629–1632CrossRefPubMed

40.

Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322. doi:10.1001/jamaoto.2014.1 CrossRefPubMed

41.

Ito Y, Miyauchi A (2015) Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 27:15–20. doi:10.1097/CCO.0000000000000143 CrossRefPubMed

42.

Renehan AG, Painter JE, Bell GD et al (2005) Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf) 62:323–330. doi:10.1111/j.1365-2265.2005.02217.x CrossRef

43.

Wassenaar MJE, Cazemier M, Biermasz NR et al (2010) Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 95:2073–2079. doi:10.1210/jc.2009-1714 CrossRefPubMed

44.

Dutta P, Bhansali A, Vaiphei K et al (2012) Colonic neoplasia in acromegaly: Increased proliferation or deceased apoptosis? Pituitary 15:166–173. doi:10.1007/s11102-011-0300-9 CrossRefPubMed

45.

Bogazzi F, Ultimieri F, Raggi F et al (2002) Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 87:2403–2406. doi:10.1210/jcem.87.5.8625 PubMed

46.

Krzentowska A, Gołkowski F, Bałdys-Waligórska A, Hubalewska-Dydejczyk A (2010) [Gastrointestinal tract polyps in acromegaly patients]. Przegla̧d Lek 67:1266–1269

47.

Rokkas T, Pistiolas D, Sechopoulos P et al (2008) Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 14:3484–3489CrossRefPubMedPubMedCentral

48.

Lois K, Bukowczan J, Perros P et al (2015) The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary 18:568–574. doi:10.1007/s11102-014-0586-5 CrossRefPubMed

49.

Dworakowska D, Gueorguiev M, Kelly P et al (2010) Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 163:21–28. doi:10.1530/EJE-09-1080 CrossRefPubMed

50.

Ron E, Gridley G, Hrubec Z et al (1991) Acromegaly and gastrointestinal cancer. Cancer 68:1673–1677CrossRefPubMed

51.

Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734. doi:10.1210/jcem.83.8.5007 PubMed

52.

Baris D, Gridley G, Ron E et al (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400. doi:10.1023/A:1015713732717 CrossRefPubMed

53.

Terzolo M, Reimondo G, Gasperi M et al (2005) Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90:84–90. doi:10.1210/jc.2004-0240 CrossRefPubMed

54.

Kauppinen-Mäkelin R, Sane T, Välimäki MJ et al (2010) Increased cancer incidence in acromegaly—a nationwide survey. Clin Endocrinol (Oxf) 72:278–279. doi:10.1111/j.1365-2265.2009.03619.x CrossRef

55.

Petroff D, Tönjes A, Grussendorf M et al (2015) the incidence of cancer among acromegaly patients: results from the German acromegaly registry. J Clin Endocrinol Metab 100:3894–3902. doi:10.1210/jc.2015-2372 CrossRefPubMed

56.

Renehan AG, Odwyer ST, Shalet SM (2001) Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 55:731–733CrossRef

Title: Complications of acromegaly: thyroid and colon
Authors: Amit Tirosh
Ilan Shimon
Publication date: 01-02-2017
Publisher: Springer US
Published in: Pituitary / Issue 1/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-016-0744-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

The surgical treatment of acromegaly

Biochemical investigations in diagnosis and follow up of acromegaly

Management of aggressive growth hormone secreting pituitary adenomas

Cabergoline in acromegaly

Acromegalic osteopathy

The genetic background of acromegaly

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage